Perbedaan Pengaruh Morphin Controlled Release 30 mg dan Oxycodone Controlled Release 20 mg Oral terhadap Nyeri Kanker

Abdul Hakim Ritonga; Yutu Solihat; Ade Veronica

doi:10.15851/jap.v5n3.1163

Perbedaan Pengaruh Morphin Controlled Release 30 mg dan Oxycodone Controlled Release 20 mg Oral terhadap Nyeri Kanker

Abdul Hakim Ritonga, Yutu Solihat, Ade Veronica

Abstract

Morfin-CR dan oksikodon-CR merupakan opioid oral untuk mengatasi nyeri kanker. Penelitian ini bertujuan mempelajari efek morfin-CR dan oksikodon-CR pada nyeri kanker dengan pengukuran visual analogue scale (VAS). Uji klinis dengan desain uji terkontrol acak tersamar ganda untuk membandingkan pengaruh analgetik morfin-CR oral dengan oksikodon-CR oral pada pasien kanker. Pasien yang telah memenuhi kriteria inklusi dibagi menjadi 2 kelompok (n=22), kelompok morfin-CR 30 mg/12jam oral dan kelompok oksikodon-CR 20 mg/12 jam oral, ditambahkan parasetamol 1.000 mg/6 jam oral. Penilaian skala nyeri dilakukan pada 4 jam, 12 jam, 24 jam, dan 48 jam setelah pemberian obat. Uji statistik menggunakan uji T berpasangan untuk sebelum perlakuan dan uji T independen untuk sesudah perlakuan pada kedua kelompok. Data karakteristik subjek VAS pada kedua kelompok homogen dan dapat diuji. Nilai VAS antara kelompok morfin-CR dan kelompok oksikodon-CR berbeda bermakna sebelum pemberian obat dengan 4 jam, 12 jam, 24 jam dan 48 jam setelah pemberian obat pertama. Tidak terdapat perbedaan bermakna antara kelompok morfin-CR dan kelompok oksikodon-CR setelah 4 jam, 12 jam, 24 jam, dan 48 jam setelah pemberian obat (p>0.05). Simpulan, terdapat perbedaan nilai VAS pada tiap-tiap kelompok sebelum dengan 4 jam, 12 jam, 24 jam, 48 jam setelah pemberian, namun tidak terdapat perbedaan antara kelompok morfin CR dan oksikodon Cr sebelum dengan 4 jam, 12 jam, 24 jam, dan 48 jam setelah pemberian.

Difference between the Effects of 30 mg Oral Morphine Controlled Release 30 mg and 20 mg Oral Oxycodone Controlled Release on Cancer Pain

Morphine-CR and oxycodone-CR are oral opioids to treat cancer pain. This study aimed to study the effects of Morphine-CR and Oxycodone-CR on cancer pain using the visual analogue scale (VAS). This was a double-blind randomized control clinical trial comparing the effect of oral morphine-CR analgesic to that of oral oxycodone-CR in cancer patients. Patients who met the inclusion were divided into 2 groups (n=22), the 30 mg/12 hours oral morphine-CR group and the 20 mg/12 hours oral oxycodone-CR added with 1,000 mg/6 hours oral aracetamol. The pain scale assessment was performed at 4 hours, 12 hours, and 48 hours after the administration of the drug. Statistical analysis using the paired T test was performed for the before treatment data and independent T test was performed for the after treatment data in both groups. The subject characteristics were homogeneous; hence, testing can be done. The VAS values between the morphine-CR group and oxycodone-CR group were significantly different between before drug administration and 4 hours, 12 hours, 24 hours, and 48 hours after the first drug administration. There was no significant difference between the morphine CR-group and oxycodone-CR group after 4 hours, 12 hours, and 48 hours of drug administration (p>0.05). Hence, there is a difference in VAS values of both groups between before drug administration and after 4 hours, 12 hours, 24 hours, and 48 hours after drug administration but no differences are found between the two groups after 4 hours, 12 hours, 24 hours, and 48 hours of drug administration.

Keywords

Morfin-CR, nyeri kanker, oksikodon-CR, visual analogue scale

Full Text:

PDF

References

Pergolizzi J, Boger RH, Budd K. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used world health organization step iii opioids. Pain Pract. 2008;8(4):287–313.

Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, dkk. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–68.

Wiffen PJ, McQuay HJ. Oral morphine for cancer pain: cochrane database of systematic reviews. Cochrane. 2016;2016(4):1–105.

Aksu M, Koyuncu I, Irfan A. The effect of morphine sulphate on life quality of cancer patient in terminal stage. Eur J Oncol Nurs. 2010;14(suppl 1):S1–62.

Wang YM, Liu ZW, Liu JL, Zhang L. Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: a meta-analysis of randomized controlled trials. Exp Ther Med. 2012;4(2):249–54.

Reid CM, Martin RM, Sterne JA, Davies AN, Hanks GW. Oxycodone for cancer-related pain: metaanalysis of randomized controlled trials. Arch Intern Med. 2007;166(8):837–43.

Riley J, Ross JR, Rutter D. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2007;14(1):56–64.

Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Systematic Rev. 2007;2007(4):1–5.

Aksu M, Koyuncu I, Irfan A. The effect of morphine sulphate on life quality of cancer patient in terminal stage. Eur J Oncol Nurs. 2010;14(1):S1–62.

Slatkinl NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opinions. 2009;25(9):2133–50.

Mercadante S, Ferrera P, Villari P, Adile C, Casuccio A. Switching from oxycodone to methadone in advanced cancer patients. Support Care Center. 2012;20(1):191–4.

Pan H, Zhang Z, Zhang Y, Xu N, Lu L, Dou C, dkk. Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain. Clin Drug Invest. 2007;27(4):259–67.

Riley J, Branford R, Droney J, Gretton S, Sato H, Kennett A, dkk. Morphine or oxycodone for cancer-related pain: a randomized open-label controlled trial. J Pain Symptom Manage. 2015;49(2):161–72.

Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain: a systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med. 2010;25(5):402–9.

Mercadante S, Ferrera P, Villari P, Adile C, Casuccio A. Switching from oxycodone to methadone in advanced cancer patients. Support Care Center. 2012;20:191–4.

Schmidt-Hansen M, Bennett M, Hilgart J. Oxycodone for cancer pain in adults patients. JAMA. 2015;314(12):1282–3.

Wang YM, Liu ZW, Liu JL, Zhang L. Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: a meta-analysis of randomized controlled trials. Exp Ther Med. 2012;4:249–52.

Silvestri B, Bandieri E, Del Prete S, Ianniello GP, Micheletto G, Dambrosio M, dkk. oxycodone controlled-release as first- choice therapy for moderate- to severe cancer pain in italian patient: result of an open label, multicentre, observational study. Clin Drug Investig. 2008;28(7):399–407.

Hu Ma, Liu Y, Huang L, Zhou JG. The adverse events of oxycodone in cancer-related pain. Medicine. 2016;95(15):1–2.

DOI: https://doi.org/10.15851/jap.v5n3.1163